Journal of Oncology Pharmacy Practice

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gressett, S. M
Right arrow Articles by Hardwicke, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gressett, S. M
Right arrow Articles by Hardwicke, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Oncology Pharmacy Practice, Vol. 12, No. 3, 131-141 (2006)
DOI: 10.1177/1078155206069242
© 2006 SAGE Publications

Management of hand-foot syndrome induced by capecitabine

Sarah M Gressett, PharmD

St Luke’s Episcopal Hospital, Houston, TX, USA

Brad L Stanford, PharmD, BCOP

School of Pharmacy, Texas Tech University Health Sciences Center, Lubbock, TX, USA

Fred Hardwicke, MD

Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA

Introduction. Capecitabine (Xeloda®) is a systemic prodrug of 5-fluorouracil (5-FU), which is administered in an oral formulation. Hand-foot syndrome (HFS) has proven to be a chronic dose-limiting toxicity of capecitabine, leading to significant morbidity in patients receiving this agent. The purpose of this review is to define the pathophysiology, risk factors, incidence and management of capecitabine-induced HFS.

Methods. Literature for this review article was collected from the following databases: PubMed, CINAHL, and the proceedings of the American Society of Clinical Oncology (ASCO) confined to the years 1995-2006. The following key terms were used in the search: hand-foot syndrome, palmar-plantar erythrodysesthesia, capecitabine, Xeloda®, colorectal cancer, and metastatic breast cancer.

Results. HFS associated with capecitabine is a serious dose-limiting toxicity. Incidence of grade 3/4 toxicity is of extreme significance, and introduces the need for dose reductions and/or interruptions in capecitabine therapy. Drug-related therapies studied include topical emollients and creams, systemic and topical corticosteroids, nicotine patch, vitamin E, pyridoxine, and COX-2 inhibitors. However, due to the lack of randomized, controlled trials with these therapies, the current mainstay of treatment for the management of this toxicity is interruption of therapy and, if necessary, dose reduction.

Conclusion. Treatment interruption or dose reduction remain the only methods shown to effectively manage HFS, but supportive measures to reduce pain and discomfort and prevent secondary infection are very important. Many other prophylactic and treatment strategies have been investigated, with pyridoxine and COX-2 inhibitors being the most promising in case reports and retrospective studies; therefore, prospective, randomized, controlled trials are needed to prove their efficacy.

Key Words: capecitabine • 5-fluorouracil • hand-foot syndrome • palmar-plantar erythrodysesthesia

References

  • Roche Laboratories. Xeloda® product information. April 2006. Retrieved from http://www.rocheusa.com/products/xeloda/pi.pdf.
  • Marse H, Van Cutsem E, Grothey A, et al. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®) . Eur J Oncol Nursing 2004; 8: S16-S30 .[CrossRef]
  • Cassidy J. Benefits and drawbacks of the use of oral fluoropyrimidines as single-agent therapy in advanced colorectal cancer . Clin Colorectal Cancer 2005; 5 (Suppl. 1): 47-50 .
  • Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients . Cancer Chemother Pharmacol 2000; 45: 291-297 .[CrossRef][Medline] [Order article via Infotrieve]
  • Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda®) . Eur J Oncol Nursing 2004; 8: S31-S40 .[CrossRef]
  • Roche Laboratories. Cancer chemotherapy and hand-foot syndrome: guidelines for coping with skin problems during cancer chemotherapy. Nutley , 2004.
  • Scheithauer W, Blum J, et al. Coming to grips with hand-foot syndrome: insights from clinical trials evaluating capecitabine . Oncology 2004; 18: 1161-1168 .[Medline] [Order article via Infotrieve]
  • Abushullaih S, Saad ED, Munsell M, et al. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience . Cancer Invest 2002; 20: 3-10 .[CrossRef][Medline] [Order article via Infotrieve]
  • Hoff PM, Pazdur R, Benner Se, et al. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer . Anticancer Drugs 1998; 9: 479-490 .[Medline] [Order article via Infotrieve]
  • Gordon KB, Tajuddin A, Guitart J, et al. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy . Cancer 1995; 75: 2169-2173 .[CrossRef][Medline] [Order article via Infotrieve]
  • Narasimhan P, Narasimhan S, Hitti IF, et al. Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature . Cutis 2004; 7: 101-106 .
  • Ferrero JM, Lassalle S, Mari M, et al. Hand-foot syndrome (HFS) in patients receiving capecitabine: a pharmacological explanation . J Clin Oncol 2006; 24 (June 20 Suppl.): 2019-2019 .[Abstract/Free Full Text]
  • Juneja V, Black G, Thornton J, et al. Hand-foot syndrome (HFS) in patients treated with capecitabine (CAP) and the role of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) . J Clin Oncol 2006; 24 (June 20 Suppl.): 8615-8615 .
  • The Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors . J Clin Oncol 1998; 16: 3537-3541 .[Abstract]
  • Heo YS, Chang HM, Kim TW, et al. Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy . J Clin Pharmacol 2004; 44: 1166-1172 .[Abstract/Free Full Text]
  • Blum J, Jone S, Buzdar A, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer . J Clin Oncol 1999; 17: 485-493 .[Abstract/Free Full Text]
  • Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study . J Clin Oncol 2000; 18: 1337-1345 .[Abstract/Free Full Text]
  • Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast cancer patients . Cancer 2001; 92: 1759-1768 .[CrossRef][Medline] [Order article via Infotrieve]
  • O’Shaughnessy J, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) versus a reference arm of intravenous CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer . Ann Oncol 2001; 12: 1247-1254 .[Abstract/Free Full Text]
  • Reichardt P, von Minckwitz G, Thuss-Patience PC, et al. Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy . Ann Oncol 2003; 14: 1227-1233 .[Abstract/Free Full Text]
  • Gradishar WJ, Meza LA, Amin B, et al. Capecitabine plus paclitaxel as front-line combination therapy for meta-static breast cancer: a multicenter phase II study . J Clin Oncol 2004; 22: 2321-2327 .[Abstract/Free Full Text]
  • Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women . J Clin Oncol 2005; 23: 2155-2161 .[Abstract/Free Full Text]
  • Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucov-orin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study . J Clin Oncol 2001; 19: 2282-2292 .[Abstract/Free Full Text]
  • Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III study . J Clin Oncol 2001; 19: 4097-4106 .[Abstract/Free Full Text]
  • O’Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results . J Clin Oncol 2002; 20: 2812-2823 .[Abstract/Free Full Text]
  • Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer . J Clin Oncol 2005; 23: 792-799 .[Abstract/Free Full Text]
  • Scheithauer W, McKendrick J, Begbie, et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial . Ann Oncol 2003; 14: 1735-1743 .[Abstract/Free Full Text]
  • Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer (X-ACT trial) . N Engl J Med 2005; 352: 2696-2704 .[Abstract/Free Full Text]
  • El-Helw L, Coleman RE. Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer . Breast 2005; 14: 368-374 .[CrossRef][Medline] [Order article via Infotrieve]
  • Feliu J, Escudero P, Llosa F, et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an Oncopaz Cooperative Group study . J Clin Oncol 2005; 23: 3104-3111 .[Abstract/Free Full Text]
  • Hennessy BT, Gauthier AM, Michaud LB, et al. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M.D. Anderson Cancer Center and a review of capecitabine toxicity in the literature . Ann Oncol 2005; 16: 1289-1296 .[Abstract/Free Full Text]
  • Blum J, Jones S, Buzdar A, et al. Capecitabine (Xeloda) in 162 patients with paclitaxel-pretreated MBC: updated results and analysis of dose modification . Eur J Cancer 2001; 37: S190-S190 .
  • O’Shaughnessy J, Blum J. A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (capecitabine) . Proc Am Soc Clin Oncol 2000; 19: 104A-104A .
  • Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin . Ann Oncol 2003; 14: 1735-1743 .[Abstract/Free Full Text]
  • Ershler WB. Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer . Oncologist 2006; 11: 325-335 .[Abstract/Free Full Text]
  • Chin SF, Tchen N, Oxa AM, et al. Use of ‘Bag Balm’ as topical treatment of palmar-plantar erythrodysesthesia syndrome (PPES) in patients receiving selected chemotherapeutic agents . Proc Am Soc Clin Oncol 2001; 20: 409a-409a .
  • Lyass O, Lotem M, Edelmann D, et al. Protective effect of amifostine (AMF) on Doxil/Caelyx-induced palmar-plantar erythrodysesthesia (PPE) in patients with advanced cancer . Proc Am Soc Clin Oncol 2001; 20: 99b-99b .
  • Pendharkar D, Goyal H. Novel and effective management of capecitabine induced hand foot syndrome . Proc Am Soc Clin Oncol 2004; 23-23 : abstract 8105.
  • Komamura H, Higashiyama M, Hashimoto K, et al. Three cases of chemotherapy-induced acral erythema . J Dermatol 1995; 22: 116-121 .[Medline] [Order article via Infotrieve]
  • Vakalis D, Loannides D, Lazaridou E, et al. Acral erythema induced by chemotherapy with cisplatin . Br J Dermatol 1998; 139: 750-751 .[CrossRef][Medline] [Order article via Infotrieve]
  • Brown J, Burck K, Black D, et al. Treatment of cytarabine acral erythema with corticosteroids . J Am Acad Dermatol 1991; 24: 1023-1025 .[Medline] [Order article via Infotrieve]
  • Hellier I, Bessis D, Sotto A, et al. High-dose methotrexate-induced bullous variant of acral erythema . Arch Dermatol 1996; 132: 590-591 .[CrossRef][Medline] [Order article via Infotrieve]
  • Hoff PM, Valero V, Ibrahim M, et al. HFS following prolonged infusion of high doses of vinorelbine . Cancer 1998; 82: 965-969 .[CrossRef][Medline] [Order article via Infotrieve]
  • Titgan MA. Prevention of palmar-plantar erythrodysesthesia associated with liposome-encapsulated doxorubicin (Doxil) by oral dexamethasone . Proc Am Soc Clin Oncol 1997; 16-16 : abstract 288.
  • Kingsley EC. 5- Fluorouracil dermatitis prophylaxis with a nicotine patch . Ann Intern Med 1994; 120: 813-813 .[Free Full Text]
  • Kara IO, Sahin B, Erkisi M. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction . Breast 2005; Sep 23; [Epub ahead of print].
  • Vail DM, Chun R, Thamm DH, et al. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model . Clin Cancer Res 1998; 4: 1567-1571 .[Abstract]
  • Vukelja SJ, Baker WJ, Burris III HA, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with Taxotere . J Natl Cancer Inst 1993; 85: 1432-1433 .[Free Full Text]
  • Fabian CJ, Molina R, Slavik M, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion . Invest New Drugs 1990; 8: 57-63 .[Medline] [Order article via Infotrieve]
  • Mortimer JE, Anderson I. Weekly fluorouracil and high-dose leucovorin: efficacy and treatment of cutaneous toxicity . Cancer Chemother Pharmacol 1990; 26: 449-452 .[CrossRef][Medline] [Order article via Infotrieve]
  • Vukelja SJ, Lombardo PA, James WD, et al. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome . Ann Intern Med 1989; 111: 688-689 .[Medline] [Order article via Infotrieve]
  • Mortimer JE, Lauman MK, Tan B, et al. Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine . J Oncol Pharm Pract 2003; 9: 161-166 .[Abstract/Free Full Text]
  • Lin E, Morris JS, Ayers GD. Effect of celecoxib-induced hand-foot syndrome and antitumor activity . Oncology 2002; 16: 31-37 .
  • Lin EH, Ayer G, Crane C, et al. Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, ameliorated capecitabine (X) hand and foot syndrome (HFS) and enhanced survival in metastatic colorectal cancer . Proc Am Soc Clin Oncol 2004; 23-23 : abstract 3584.
  • Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention . N Engl J Med 2005; 352: 1071-1080 .[Abstract/Free Full Text]
  • Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial . N Engl J Med 2005; 352: 1092-1102 .[Abstract/Free Full Text]
  • Nussmeier NA, Whelton AA, Brown MT, et al. Complications of COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery . N Engl J Med 2005; 352: 1081-1091 .[Abstract/Free Full Text]
  • Poole C, Gardiner J, Twelves C, et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients . Cancer Che-mother Pharmacol 2002; 49: 225-234 .[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
J. L. Yen-Revollo, R. M. Goldberg, and H. L. McLeod
Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines?
Clin. Cancer Res., January 1, 2008; 14(1): 8 - 13.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gressett, S. M
Right arrow Articles by Hardwicke, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gressett, S. M
Right arrow Articles by Hardwicke, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?